Pharmaceutical Technology

APRIL 16, 2023

But with the advent of injection site absorption enhancers, drug delivery device innovations, as well as the recent primary container options, the practical subcutaneous self-administration of large-volume parenterals is becoming possible. mL devices – all of which are developed by SHL Medical. autoinjector.

Protein 130

Protein Containment Drug Delivery Drugs 130

The Pharma Data

NOVEMBER 2, 2020

XPhyto is currently focused on securing industrial scale production of psychedelic APIs and the standardization of drug formulations for the delivery of such APIs. The biotechnology production development program commenced in October 2020 with completion expected in September 2021. About XPhyto Therapeutics Corp.

Production 52

Production Development Drug Delivery Drugs 52

XTalks

MAY 30, 2023

The VTT Technical Research Centre of Finland has addressed this issue by developing a fully recyclable, modular ECG patch constructed from VTT’s novel cellulose e-skin material. The patch itself is made of biodegradable nanocellulose and contains no plastic additives.

Drug Delivery 98

Drug Delivery Drug Delivery Systems Manufacturing Contamination 98

XTalks

JANUARY 17, 2023

The US Food and Drug Administration (FDA) granted approval to AstraZeneca’s Airsupra (albuterol/budesonide), formerly known as PT027, for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma attacks in individuals aged 18 years and older who have asthma.

FDA Approval 97

FDA Approval Containment Allergies Drugs 97

STAT News

NOVEMBER 3, 2022

The companies allege Moderna’s vaccine uses their technology for a drug-delivery system without permission. Citing The single-dose vaccine candidate is a combination of Pfizer’s mRNA-based flu shot and the Omicron-tailored Covid-19 booster shot developed by both companies.

Vaccination 97

Vaccination Vaccine Drug Delivery Systems Sales 97

The Pharma Data

JANUARY 31, 2021

(CSI ® ) (NASDAQ: CSII) announced today that it has partnered with Chansu Vascular Technologies, LLC (CVT) to develop novel peripheral and coronary everolimus drug-coated balloons (DCBs). This collaboration enables us to develop a new class of DCBs that we believe will improve patient outcomes.”. Cardiovascular Systems, Inc.,

Development 52

Development Drugs Production Containment 52

The Pharma Data

NOVEMBER 9, 2020

Psilocybin, mescaline, LSD, MDMA, DMT and other psychedelic compounds added to exclusive dealing agreement for the development of psychedelic-based therapeutics. Dr. Löbenberg with respect to exclusive commercial development rights under his cannabis licences and to related intellectual property. The Company and Prof.

Development 40

Development Drugs Drug Delivery Production 40

pharmaphorum

NOVEMBER 17, 2021

The Future of Drug Delivery and Combination Product Device Design. The pre-filled syringes industry is growing at an exponential rate with innovations in parenteral delivery device development to aid self-administration and deliver biologics, high concentration, and large-volume drug products.

Drugs 52

Drugs Drug Delivery Engineer Production 52

The Pharma Data

OCTOBER 27, 2020

“Applying 3a’s proprietary enhanced RNA technology to PCR testing was a logical next step in our product development pipeline,” said Dr. . “We are currently developing two saliva-based tests to detect SARS-CoV-2 RNA. . VANCOUVER, BC / ACCESSWIRE / October 28, 2020 / XPhyto Therapeutics Corp.

RNA 52

RNA Drug Delivery Production In-Vitro 52

XTalks

JULY 28, 2020

Excipients can take many forms, such as bulking agents, binders, coatings and colourants, and they are chosen based on their ability to aid in drug delivery, administration and even in pill identification and prevention of counterfeiting. But just how inert are these excipients?

Protein 103

Protein Drugs In-Vitro Scientist 103

The Pharma Data

DECEMBER 20, 2020

With this acquisition we are expanding our product pipeline to include psychedelic therapeutics, incorporating elements of our IP around drug delivery technology in which we already have prototypes developed, which we believe will propel us towards clinical studies relatively quickly. Ahmad Doroudian, CEO of BetterLife.

Drug Delivery 52

Drug Delivery Containment Production Development 52

Roots Analysis

MAY 24, 2024

In the dynamic landscape of the healthcare sector, the evolution of drug delivery systems plays a significant role in transforming the management of chronic diseases. They are generally used in combination with primary containers, such as prefilled syringes and cartridges.

Drug Delivery 40

Drug Delivery Containment Contamination Production 40

Roots Analysis

MARCH 8, 2023

Over time, various research studies have demonstrated the potential of exosomes ( membrane bound extracellular vesicles) in disease diagnosis, drug delivery and therapeutic applications. Targeted Drug Delivery: Ability to cross blood brain barrier cause lesser systemic effects and low toxicity.

RNA 52

RNA Drug Delivery DNA Development 52

The Pharma Data

DECEMBER 28, 2020

is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. About BetterLife Pharma Inc.

Containment 52

Containment Drug Delivery Compliance Marketing 52

The Pharma Data

JANUARY 27, 2021

Construction of commercial drug manufacturing facility in Germany. Development of oral biosensor and contract development & manufacturing. Psychedelic transdermal and sublingual drug formulation development. Four clinical studies in neurological indications in 2021.

Drugs 52

Drugs Manufacturing Drug Delivery Production 52

The Pharma Data

JANUARY 3, 2021

04, 2021 (GLOBE NEWSWIRE) — TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced today that its subsidiary, InspirMed Inc., The inhalable liposome drug was also found to be less toxic than the free drug.

Clinical Trials 52

Clinical Trials Clinical Trials Containment Development 52

The Pharma Data

OCTOBER 20, 2020

21, 2020 (GLOBE NEWSWIRE) — TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage, specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced the appointment of Thomas H. Earlier in his career, he ran business-development functions at Amgen and Baxter. and TAIPEI, Taiwan, Oct.

Licensing 40

Licensing Licensing Drug Delivery Business Development 40

The Pharma Data

NOVEMBER 26, 2020

This novel nanoparticle formation technology provides hope for improving the possibilities and probabilities of developing better medicines for patients and it expands Nanoform’s reach into the growing biological market. ” Prof. ” Prof. Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806.

Containment 52

Containment Medicine Development Bioavailability 52

The Pharma Data

JANUARY 25, 2021

Optimised formulations have been developed for the two internal pipeline programmes, MTD211 and MTD219, with the former undergoing and the latter shortly to beginin vivostudies. ” This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR). Panobinostat Licence. Strategic Review.

Containment 52

Containment Drug Delivery Licensing Licensing 52

XTalks

AUGUST 30, 2022

Developing strategies can often fall under the responsibilities of directors and managers of companies. The pharmaceutical industry deals with threats such as product liability, cyberthreats, supply chain disruptions, competition from generic drugs and more. Therefore, strategic intent is vital when making decisions.

Life Science 105

Life Science Generic Drugs Drug Delivery Compliance 105

The Pharma Data

JANUARY 18, 2021

BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, is pleased to announce that Health Canada has confirmed that 2-bromo-LSD is not a controlled substance. VANCOUVER, Jan.

Containment 40

Containment Production Drug Delivery Regulation 40

The Pharma Data

JANUARY 27, 2021

BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, announces it has entered into an agreement with Eurofins Discovery for TD-0148A’s U.S. VANCOUVER, Jan. Source link.

In-Vitro 52

In-Vitro Containment Drugs Production 52

Roots Analysis

JANUARY 17, 2024

They offer several advantages over traditional drug delivery systems ( such as vials and syringes ), including reduced chances of dosing errors, increased patient compliance and decreased risk of microbial contamination. However, this needle system does not contain a proper locking system, therefore, increased the chances of leakage.

Drug Delivery 40

Drug Delivery Contamination Drugs Production 40

The Pharma Data

DECEMBER 14, 2020

BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech focused on the development and commercialization of cutting edge treatments, today announced the value proposition of its acquisition of Transcend Biodynamics, LLC ’s (“Transcend”) manufacturing patent “Process of synthesizing 2-Bromo-LSD.”.

Drug Delivery 40

Drug Delivery Containment Manufacturing Drugs 40

Roots Analysis

MARCH 16, 2023

In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent. It is worth noting that several companies have begun to develop mRNA-based cancer immunotherapies and vaccines for infectious diseases.

Vaccination 52

Vaccination Vaccine DNA Protein 52

The Pharma Data

JANUARY 3, 2021

Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform’s platform technologies. The Company focuses on reducing attrition in clinical trials and on enhancing drug molecules’ formulation performance through its nanoforming services.

Containment 40

Containment Bioavailability Clinical Trials Clinical Trials 40

Roots Analysis

JUNE 6, 2024

The continuous evolution of autoinjectors reflects a significant shift towards empowering patients to take control of their treatment, ensuring timely and accurate medication delivery for better health management. Reduced Medication Errors: As the autoinjectors contain the exact dose of medication, they enable reduced dosing errors.

Medicine 40

Medicine Drug Delivery Manufacturing Marketing 40

The Pharma Data

JANUARY 17, 2021

The Company is on the cusp of transformational change as product development programs advance from the laboratory to the clinic. In addition to COVID-19 products, XPhyto and its partner 3a, are developing and commercializing a portfolio of low-cost oral biosensors. Diagnostics. “2020 was a very productive year for XPhyto.

Production 40

Production Development Drug Delivery Drugs 40

The Pharma Data

NOVEMBER 4, 2020

Thoresen holds a law degree from the top-ranked University of Oslo and core competencies in strategy and organizational development, operational execution, and industry and government relations. About XPhyto Therapeutics Corp. XPhyto Therapeutics Corp. Forward looking statements.

Drug Delivery 40

Drug Delivery Production Manufacturing Development 40

The Pharma Data

OCTOBER 27, 2020

is a research and development company that develops topical and transdermal consumer products including DermSafe, all made with patented Invisicare® skin delivery technology. The technology enhances the delivery of ingredients to and through the skin and is protected by patents in eleven countries. Ovation Science Inc.

Sales 52

Sales Production Drug Delivery Development 52

The Pharma Data

DECEMBER 2, 2020

Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced the pricing of its previously announced underwritten public offering of 7,645,259 shares of its common stock at a public offering price of $3.27 SAN DIEGO, Dec.

In-Vitro 40

In-Vitro Sales Containment Development 40

The Pharma Data

JUNE 26, 2021

Roche’s Chief Medical Officer and Head of Global Product Development. “If Roche has a robust phase III clinical development programme underway for PDS, including the Portal, Pagoda and Pavilion studies. 11,12 It develops when new and abnormal blood vessels grow uncontrolled under the macula, causing swelling, bleeding and/or fibrosis.

Drug Delivery 52

Drug Delivery Clinical Trials Clinical Trials Medicine 52

The Pharma Data

DECEMBER 17, 2020

With experiences attained in licensing and business development functions from Amgen, Baxter and Johnson & Johnson, Mr. Bliss introduced himself in Mandarin Chinese. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. SOUTH SAN FRANCISCO, Calif.

Clinical Trials 40

Clinical Trials Clinical Trials Trials Containment 40

The Pharma Data

NOVEMBER 4, 2020

(TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (“R&D”) and manufacturing capabilities, today announced that it has entered into an exclusive agreement with Juyou-Biotechnology Co.

Licensing 40

Licensing Licensing Dermatology Production 40

The Pharma Data

DECEMBER 2, 2020

is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Certain entities affiliated with Athyrium Capital Management, LP (“Athyrium”), one of Progenity’s affiliates, have agreed to acquire up to $103.5

Sales 40

Sales In-Vitro Containment Development 40

The Pharma Data

APRIL 27, 2021

A Minipump Continuous Drug Infusion Dog Model System to Identify Candidate Drugs and Drug Delivery Rates for Intracameral IOP-lowering Implants. A Retrospective Analysis: Visual Field Progression and Visual Acuity following Administration of Brimonidine Drug Delivery System. Sunday, May 2. Monday, May 3.

Research 40

Research Drug Delivery Systems Drug Delivery Production 40

FDA Law Blog

MARCH 12, 2024

Failing to list the patents, as AstraZeneca points out, “may expose the reference drug sponsor to legal risks,” as “at least one generic applicant has argued that a failure to do so constitutes a violation of the antitrust laws by depriving the applicant of information that would have affected its decision whether to develop a generic product.”

Drugs 45

Drugs Drug Delivery Systems Regulation Production 45